Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Qiagen EGFR Assay Approved in Japan as CDx to Pfizer NSCLC Drug

Qiagen EGFR Assay Approved in Japan as CDx to Pfizer NSCLC Drug

Jan 16, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Qiagen said Wednesday that its Therascreen EGFR RGQ PCR kit has been approved by the Japanese Pharmaceuticals and Medical Device Agency as a companion diagnostic with Pfizer's Vizimpro (dacomitinib) for EGFR mutation-positive, inoperable, or recurrent non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. Roche SARS-CoV-2 Lateral Flow Antigen Test Could Meet Significant Demand

    Premium

  2. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  3. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  4. BARDA Awards $684K to Luminex for Enhanced COVID-19 Multiplex Antibody Test

  5. FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.